Difference between revisions of "Team:Tianjin/Demonstrate"

Line 224: Line 224:
 
   <h4>Obtaining the chassis </h4>
 
   <h4>Obtaining the chassis </h4>
 
<hr>
 
<hr>
   <p>Aiming to achieve MTS for environmental use, it is essential to make sure that when the <i>MAT</i> locus has DSB (double strands break) cleaved by <i>HO</i>, our type-a (<i>MATa</i>) yeast can only become type-α (<i>MATα</i>). Therefore, we used a <i>Ura-tag</i> to replace the<i> HMRa</i> domain in <i>chromosome Ⅲ</i>. In this way the <i>HMRa</i> will no longer be the donor for the homologous recombination in the repairing process for MAT cleavage. Since the change of mating type may appear successively, there is a great possibility that the same type haploid mate with each other. To avoid the existence of meaningless mating, we built an vector to express <i>MATα</i> genes to produce <i>a1-α2 stable corepressor</i> so that the haploid will regard itself as a diploid and prevent mating unless the <i>MATa</i> locus changes to the other one. After selection, by homologous recombination, we deleted the <i>Ura-tag</i> for further usage. We selected the target colonies (<i>SynⅩ-dUra</i>) via <i>5-FOA</i> plates. </p>
+
   <p>Aiming to achieve MTS for environmental use, it is essential to make sure that when the <i>MAT</i> locus has DSB (double strands break) cleaved by <i>HO</i>, our type-a (<i>MATa</i>) yeast can only become type-α (<i>MATα</i>). Therefore, we used a <i>Ura-tag</i> to replace the<i> HMRa</i> domain in <i>chromosome Ⅲ</i>. In this way the <i>HMRa</i> will no longer be the donor for the homologous recombination in the repairing process for MAT cleavage. Since the change of mating type may appear successively, there is a great possibility that the same type haploid mate with each other. To avoid the existence of meaningless mating, we built an vector to express <i>MATα</i> genes to produce <i>a1-α2 stable corepressor</i> so that the haploid will regard itself as a diploid and prevent mating unless the <i>MATa</i> locus changes to the other one. After selection, by homologous recombination, we deleted the <i>Ura-tag</i> for further usage. We selected the target colonies (<b><i>SynⅩ-dUra</i></b>) via <i>5-FOA</i> plates. </p>
 
   <img src="https://static.igem.org/mediawiki/2017/7/7e/Tianjin-ho-result-1.jpeg">
 
   <img src="https://static.igem.org/mediawiki/2017/7/7e/Tianjin-ho-result-1.jpeg">
   <p>Fig.1.We successfully acquired the target yeasts as our chassis (<i>SynⅩ-dUra</i>).</p>
+
   <p>Fig.1.We successfully acquired the target yeasts as our chassis (<b><i>SynⅩ-dUra</i></b>).</p>
 
   <h4> The result for constructing the <i>Gal</i> systems</h4>
 
   <h4> The result for constructing the <i>Gal</i> systems</h4>
 
<hr>
 
<hr>
 
   <p>In this pathway, we chose <i>Gal1</i> as our inducible promoter for the expression of <i>HO</i> gene, <i>CYC1</i> as the terminator, and <i>PRS416</i>(with <i>Ura-tag</i>) as our vector. As for segments ligation, we designed the cutting sites for <i>Bsa1</i> enzyme in each part, hoping to achieve seamless ligation of these three parts.</p>
 
   <p>In this pathway, we chose <i>Gal1</i> as our inducible promoter for the expression of <i>HO</i> gene, <i>CYC1</i> as the terminator, and <i>PRS416</i>(with <i>Ura-tag</i>) as our vector. As for segments ligation, we designed the cutting sites for <i>Bsa1</i> enzyme in each part, hoping to achieve seamless ligation of these three parts.</p>
<p>We adopted the PCR method to amplify the <i>Gal1-part</i> and <i>CYC1-part</i> from a <i>Gal1-Vika</i> plasmid we had used in our former lab work with specially designed primers for this procedure. After PCR, the <i>Gal1</i> has the cutting sites for <i>SalⅠ</i>and <i>BsaⅠ</i>on both ends, and <i>CYC1</i> has that for <i>BsaⅠ</i>and <i>BamhⅠ</i>on both ends. Meanwhile, the <i>HO</i> gene was obtained by gene synthesis, flanked by specific hangtags for <i>BsaⅠ</i>in order to be cohesive with <i>Gal1</i> (upstream) and <i>CYC1</i> (downstream). Thus, we have built our composite part (<i>GHC</i>).</p>
+
<p>We adopted the PCR method to amplify the <b><i>Gal1-part</i></b> and <b><i>CYC1-part</i></b> from a <i>Gal1-Vika</i> plasmid we had used in our former lab work with specially designed primers for this procedure. After PCR, the <i>Gal1</i> has the cutting sites for <i>SalⅠ</i>and <i>BsaⅠ</i>on both ends, and <i>CYC1</i> has that for <i>BsaⅠ</i>and <i>BamhⅠ</i>on both ends. Meanwhile, the <i>HO</i> gene was obtained by gene synthesis, flanked by specific hangtags for <i>BsaⅠ</i>in order to be cohesive with <i>Gal1</i> (upstream) and <i>CYC1</i> (downstream). Thus, we have built our composite part (<i>GHC</i>).</p>
 
<p>After the ligation of<b><i>GHC</i></b> and <i>PRS416</i> Plasmid (<b><i>GHC-416</i></b>), we transformed the E. coli for the augment of our new plasmid——<b><i>GHC-416</i></b>. We examined the transformation result by PCR method to amplify the <i>HO</i> gene in the E. coli which we randomly selected in the plate.   
 
<p>After the ligation of<b><i>GHC</i></b> and <i>PRS416</i> Plasmid (<b><i>GHC-416</i></b>), we transformed the E. coli for the augment of our new plasmid——<b><i>GHC-416</i></b>. We examined the transformation result by PCR method to amplify the <i>HO</i> gene in the E. coli which we randomly selected in the plate.   
 
</p>
 
</p>

Revision as of 11:49, 27 October 2017

/* OVERRIDE IGEM SETTINGS */

Demonstrate